文献速递临床试验与 GCP

地塞米松在ARDS合并COVID-19患者中的效果(REMED试验)——一项前瞻性、多中心、开放标签、平行组、随机对照试验的研究方案

Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)-study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial.
PubMed 文献 · Trials · 2022-01-15

REMED试验为前瞻性、多中心、开放标签、平行组随机对照试验,在捷克共和国10所大学医院ICU纳入300例确诊COVID-19所致中重度ARDS的成人患者,比较地塞米松20mg(第1-5天20mg,第6-10天10mg)与6mg每日一次静脉给药共10天的优效性;主要终点为随机化后28天无呼吸机天数,随访至360天。

要点

  • REMED试验比较地塞米松20mg递减方案与6mg方案在中重度ARDS合并COVID-19机械通气患者中的疗效与安全性。
  • 主要终点为随机化后28天无呼吸机天数(VFDs),计划纳入300例,随访360天。
  • 目前COVID-19肺炎需氧或机械通气患者推荐地塞米松6mg/日,但该剂量正被重新评估。

核心结论

  • 研究旨在比较两种不同剂量地塞米松在中重度ARDS接受机械通气患者中的疗效与安全性。

研究设计与样本

  • REMED为前瞻性、多中心、开放标签、平行组、随机对照试验,检验地塞米松20mg方案对6mg方案的优效性。
  • 计划纳入300例确诊COVID-19所致中重度ARDS的成人患者,按1:1比例随机分配至两个治疗组。
  • 分层因素为年龄、Charlson合并症指数、CRP水平和试验中心。
  • 研究在捷克共和国10所大学医院的ICU进行,随机化后随访360天。

主要发现

  • 地塞米松20mg组方案为第1-5天20mg,随后第6-10天10mg;6mg组为每日一次静脉给药6mg,共10天。
  • 主要终点为随机化后28天无呼吸机天数(VFDs)。
  • 次要终点包括随机化后60天全因死亡率、炎症标志物动态、第14天WHO临床进展量表变化、与糖皮质激素相关的不良事件以及随机化后90天Barthel指数评估的独立性。
  • 长期结局评估180天和360天时的死亡和生活质量长期后果。

临床怎么用

  • 目前对需要氧疗或机械通气的COVID-19肺炎患者推荐地塞米松6mg/日,但该剂量正被重新评估,可能遗漏重要治疗潜力或可能阻止更高剂量糖皮质激素的潜在有害效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since December 2019, SARS-CoV-2 virus has infected millions of people worldwide. In patients with COVID-19 pneumonia in need of oxygen therapy or mechanical ventilation, dexamethasone 6 mg per day is currently recommended. However, the dose of 6 mg of dexamethasone is currently being reappraised and may miss important therapeutic potential or may prevent potential deleterious effects of higher doses of corticosteroids. METHODS: REMED is a prospective, open-label, randomised controlled trial testing the superiority of dexamethasone 20 mg (dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10) vs 6 mg administered once daily intravenously for 10 days in adult patients with moderate or severe ARDS due to confirmed COVID-19. Three hundred participants will be enrolled and followed up for 360 days after randomization. Patients will be randomised in a 1:1 ratio into one of the two treatment arms. The following stratification factors will be applied: age, Charlson Comorbidity Index, CRP levels and trial centre. The primary endpoint is the number of ventilator-free days (VFDs) at 28 days after randomisation. The secondary endpoints are mortality from any cause at 60 days after randomisation; dynamics of the inflammatory marker, change in WHO Clinical Progression Scale at day 14; and adverse events related to corticosteroids and independence at 90 days after randomisation assessed by the Barthel Index. The long-term outcomes of this study are to assess long-term consequences on mortality and quality of life at 180 and 360 days. The study will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic. DISCUSSION: We aim to compare two different doses of dexamethasone in patients with moderate to severe ARDS undergoing mechanical ventilation regarding efficacy and safety. TRIAL REGISTRATION: EudraCT No. 2020-005887-70. ClinicalTrials.gov NCT04663555. Registered on December 11, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Maláska J, Stašek J, Duška F, et al. Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)-study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial. Trials. 2022. PMID: 35033182. doi:10.1186/s13063-021-05963-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。